In adults with psoriasis, ustekinumab showed the highest drug survival rate in biologic-naive patients but had reduced effectiveness in biologic-experienced patients.

Conclusions: With the development of recombinant DNA techniques, it has become possible to develop new biologic therapies that can be designed to specifically alter physiological responses. These new ...

Maintenance therapy with subcutaneous imsidolimab allowed all treated patients to remain flare-free throughout the GEMINI-2 study period.

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Patients with psoriasis who have active cancer or who have had cancer within 5 years can safely use biologics.

A review of 10 articles finds that nearly 9% of adverse event (AE) reports with biologics used to treat psoriasis were gastrointestinal (GI)-related and suggests that the relative rate may be higher ...

Black patients on Medicaid less likely to use the newer therapies ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and overweight or obesity, according to topline results announced by Eli ...

Please provide your email address to receive an email when new articles are posted on . The majority of patients and clinicians agreed with the use of as-needed biologic therapy for psoriasis.

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...